“Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer” has been added to your cart. View cart

Article: Luspatercept in lower-risk myelodysplastic syndromes: Belgian real-life data into perspective

€3.03

SKU: product-article-45241 Category: General

Description
Reviews (0)

Description

Luspatercept in lower-risk myelodysplastic syndromes: Belgian real-life data into perspective

Reviews

There are no reviews yet.

Be the first to review “Article: Luspatercept in lower-risk myelodysplastic syndromes: Belgian real-life data into perspective”

You must be logged in to post a review.

Top

Article: Luspatercept in lower-risk myelodysplastic syndromes: Belgian real-life data into perspective

Description

Reviews

Related products

Article: Highlights in breast cancer

Article: Highlights in squamous cell carcinoma of the head and neck

Article: INTRODUCTION

Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer